Aripiprazole ^ data on efficacy and associated mortality
ثبت نشده
چکیده
El-Sayeh et al (2006) raise some important issues regarding the design and reporting of clinical trials. However, we feel that the conclusion that ‘aripiprazole has been licensed despite the fact that few reliable data on this drug are publicly available’ merits further clarification. Aripiprazole was first approved in November 2002 in the USA, and in 2004 in Europe, based on the submission of a substantial body of evidence to the regulatory authorities on more than 4000 patients. However, BristolMyers Squibb and Otsuka Pharmaceuticals are committed to reporting trial results as completely as possible, and publication of pivotal studies has taken place subsequent to approval. All the aripiprazole clinical studies were conducted in accordance with regulatory requirements and using accepted standards (Marder et al, 2003; Naber & Lambert, 2004). Such studies have inherent restrictions, and we recognise that patients enrolled may not always reflect those seen in everyday care. We understand the value of all study types – randomised controlled trials, naturalistic, retrospective, observational – in helping to determine the benefit–risk profile, and have recently completed a series of studies with more naturalistic designs and with large sample sizes, to explore the benefits in a wide range of patients (Tandon et al, 2006; Kerwin et al, 2007, details of the other study can be obtained from http://www.clinical trials.gov, trial number NCT00237939). These complete studies support the profile of aripiprazole established in the clinical studies reviewed by El-Sayeh et al in their systematic analysis. With respect to the suggestion that deaths occurring during the aripiprazole studies have not been widely reported, it is our practice to report any deaths or adverse events applicable to a study and we have done so consistently in our publications. Deaths unfortunately do occur during studies, just as they do in real-world situations. We are committed to continued openness and disclosure of clinical study results, and as such will continue to work closely with El-Sayeh et al.
منابع مشابه
Diplopia Caused by Aripiprazole in a Depressed Patient With Healthy Eyesrt
Background: Diplopia, or double vision, is a common ophthalmologic complaint with many underlying causes, ocular and neurological. Aripiprazole has been reported to have fewer adverse effects and better efficacy than other atypical antipsychotics. Although ocular side effects of aripiprazole are not remarkable, two cases of diplopia associated with aripiprazole have been reported in the litera...
متن کاملManagement of psychosis in patients with Alzheimer’s disease: focus on aripiprazole
Psychosis of Alzheimer's disease (AD) is characterized by delusions or hallucinations and may be associated with agitation, negative symptoms or depression. There are no psychotropic medications that are approved by the US FDA for the treatment of psychosis of AD. However, atypical antipsychotics have been widely used and recommended by geriatric experts in the management of psychosis of AD in ...
متن کاملEfficacy and Safety of Aripiprazole for Treatment of Irritability in Children with Autistic Disorder: An Open-Label Study
متن کامل
ABILIFY (aripiprazole) Tablets ABILIFY DISCMELT (aripiprazole) Orally Disintegrating Tablets ABILIFY (aripiprazole) Oral Solution ABILIFY (aripiprazole) Injection FOR INTRAMUSCULAR USE ONLY Initial U.S. Approval: 2002 WARNINGS: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS and SUICIDALITY AND ANTIDEPRESSANT DRUGS
---------------------------INDICATIONS AND USAGE---------------------------ABILIFY is an atypical antipsychotic indicated as oral formulations for the: Treatment of schizophrenia (1.1) • Adults: Efficacy was established in four 4-6 week trials and one maintenance trial in patients with schizophrenia (14.1) • Adolescents (ages 13-17): Efficacy was established in one 6-week trial in patients with...
متن کاملABILIFY (aripiprazole) Tablets ABILIFY DISCMELT (aripiprazole) Orally Disintegrating Tablets ABILIFY (aripiprazole) Oral Solution ABILIFY (aripiprazole) Injection FOR INTRAMUSCULAR USE ONLY Initial U.S. Approval: 2002 WARNINGS: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS and SUICIDALITY AND ANTIDEPRESSANT DRUGS
---------------------------INDICATIONS AND USAGE---------------------------ABILIFY is an atypical antipsychotic indicated as oral formulations for the: Treatment of schizophrenia (1.1) • Adults: Efficacy was established in four 4-6 week trials and one maintenance trial in patients with schizophrenia (14.1) • Adolescents (ages 13-17): Efficacy was established in one 6-week trial in patients with...
متن کاملAripiprazole in bipolar disorder: clinical strategies to maximize efficacy and tolerability
A number of double-blind, randomized, controlled trials have confirmed the clinical efficacy of aripiprazole in bipolar disorder and schizophrenia. Aripiprazole is the prototype of the ‘third generation’ atypical antipsychotics, or dopamine-serotoninstabilizers and is characterized by a relatively low risk of inducing metabolic adverse effects, causing sedation and other side effects such as hy...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2007